FDA warned online seller Ketamine Troche Store that its website sells unapproved, misbranded ketamine drugs without prescriptions.
What happened
FDA reviewed the website www.ketaminetrochestore.com from January 9 to January 16, 2026, and found ketamine and esketamine products offered for sale with claims to treat depression, anxiety, and chronic pain. The products named were "Ketamine Liquid," "Ketamine Suppository," "Ketamine Nasal Spray" (esketamine), and "Ketamine 100 mg Troche." FDA said none of these has an FDA-approved application, and that the site sells them without requiring a prescription.
What FDA found
The company sells ketamine drugs that have no FDA-approved application, which the law calls unapproved new drugs.
FD&C Act sections 505(a) and 301(d) (21 U.S.C. 355(a), 331(d))The "Ketamine 100 mg Troche" is sold without prescriptions for individual patients and the seller is not a registered outsourcing facility, so it does not qualify for the compounding exemptions.
FD&C Act sections 503A and 503B (21 U.S.C. 353a, 353b); sections 505(a) and 301(d)The product labels do not give adequate directions for use, which prescription drugs cannot have for a layperson, so the drugs are misbranded.
FD&C Act section 502(f)(1) (21 U.S.C. 352(f)(1))The site offers prescription drugs without requiring a prescription from a licensed practitioner, which misbrands the drugs.
FD&C Act sections 503(b)(1) and 301(k) (21 U.S.C. 353(b)(1), 331(k))
What FDA wants
FDA tells the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers, and to send a written response within 15 business days describing the corrections, how it will prevent repeat violations, and supporting documents.
Who should pay attention
- online and telehealth sellers of ketamine products
- pharmacies and compounders that supply ketamine troches or liquids
- clinics and brands whose ketamine products could be resold through third-party websites
This is a summary. Read the original letter on fda.gov.